Publications by authors named "Soussain C"
Primary central nervous system lymphoma of the spinal cord: A LOC network cohort study.
Rev Neurol (Paris)
December 2024
Purpose: Primary central nervous system lymphoma (PCNSL) mainly affects the brain (>90% cases); there are very little data pertaining to PCNSL involving the spinal cord.
Methods: We retrospectively selected from the French LOC network database adult immunocompetent patients diagnosed with PCNSL involving the spinal cord between 2011 and 2022.
Results: Of the 2043 patients records retrieved from the database, 16 patients (median age: 62.
Article Synopsis
- Intravascular lymphoma is a rare B-cell lymphoma that primarily affects small blood vessels and often involves the central nervous system (CNS), making early diagnosis challenging due to non-specific symptoms.
- A study analyzed data from 17 patients, finding that most experienced sudden neurological episodes, rapid cognitive decline, and unique MRI characteristics, alongside other clinical signs such as elevated LDH levels.
- The research identified key features, or "red flags," that could aid in quicker diagnosis of CNS-involving intravascular lymphoma, emphasizing the importance of recognizing these indicators.
Article Synopsis
- Vitreoretinal lymphoma (VRL) has a poor prognosis due to high relapse rates in the central nervous system, requiring treatments like high-dose chemotherapy with autologous stem cell transplantation (HCT-ASCT).
- A study analyzed 38 adult patients treated with HCT-ASCT for isolated VRL over 11 years, showing that 84% received a thiotepa-based regimen, with some patients experiencing serious side effects.
- Results revealed a significant relapse rate, particularly in the brain, but the strategy showed relatively good median survival rates: 96 months for progression-free survival and 92 months overall.
Article Synopsis
- * A panel of European physicians developed consensus statements to guide the prevention and treatment of DME, focusing on using glucarpidase and supportive measures like hyperhydration and urine alkalinization.
- * Early identification of DME is crucial for timely interventions, which may include increased hydration, high-dose leucovorin, and glucarpidase when needed to mitigate risks associated with DME.
Background: Results of conventional induction chemotherapies in primary central nervous system lymphoma (PCNSL) need to be improved. Ibrutinib, a BTK inhibitor, and lenalidomide, an immunomodulatory drug, have shown promising results at relapse, supporting to further assess their individual use in combination with high-dose methotrexate-based chemotherapy.
Methods: Patients with newly diagnosed PCNSL were randomized to receive four 28-day cycles of ibrutinib or lenalidomide in combination with R-MPV (rituximab, methotrexate, procarbazine, vincristine and prednisone) in a 3 + 3 design.
Purpose: Immunosuppression is a well-established risk factor for primary central nervous system lymphomas (PCNSLs), which present in this context distinct radiological characteristics. Our aim was to describe the radiological evolution of treated PCNSL in immunocompromised patients and suggest adapted MRI response criteria.
Methods: We conducted a multicenter retrospective study of patients from the French LOC, K-Virogref and CANCERVIH network databases and enrolled adult immunocompromised patients with newly diagnosed PCNSL.
This EHA-ESMO Clinical Practice Guideline provides key recommendations for managing primary DLBCL of the CNS.The guideline covers clinical, imaging and pathological diagnosis, staging and risk assessment, treatment and follow-up.Algorithms for first-line and salvage treatments are provided.
View Article and Find Full Text PDFObjectives: Despite a high response rate at the first evaluation during induction chemotherapy, the risk of early relapse remains high and unpredictable in primary CNS lymphomas (PCSNLs). We aimed to assess the prognostic value of early IL-10 levels in CSF (e-IL-10) after 2 months of induction chemotherapy.
Methods: We retrospectively selected from the LOC (Lymphomes Oculo-Cérébraux) network database patients with PCSNLs who had complete or partial response at the 2-month evaluation of a high-dose methotrexate-based first-line chemotherapy for whom e-IL-10 was available.
Primary central nervous system lymphoma (PCNSL) is a rare and highly aggressive lymphoma entirely localized in the central nervous system or vitreoretinal space. PCNSL generally initially responds to methotrexate-containing chemotherapy regimens, but progressive or relapsing disease is common, and the prognosis is poor for relapsed or refractory (R/R) patients. PCNSL is often characterized by activation of nuclear factor kappa B (NF-κB) due to mutations in the B-cell receptor (BCR) or toll-like receptor (TLR) pathways, as well as immune evasion.
View Article and Find Full Text PDFThe prognosis of relapsed primary central nervous system lymphoma (PCNSL) remains dismal. CAR T-cells are a major contributor to systemic lymphomas, but their use in PCNSL is limited. From the LOC network database, we retrospectively selected PCNSL who had leukapheresis for CAR-T cells from the third line of treatment, and, as controls, PCNSL treated with any treatment, at least in the third line and considered not eligible for ASCT.
View Article and Find Full Text PDFBackground: The purpose of our study was to assess the predictive and prognostic role of 2-18F-fluoro-2-deoxy-d-glucose (FDG) positron emission tomography (PET)/MRI during high-dose methotrexate-based chemotherapy (HD-MBC) in de novo primary central nervous system lymphoma (PCNSL) patients aged 60 and above.
Methods: This prospective multicentric ancillary study included 65 immunocompetent patients who received induction HD-MBC as part of the BLOCAGE01 phase III trial. FDG-PET/MRI were acquired at baseline, post 2 cycles (PET/MRI2), and posttreatment (PET/MRI3).
Article Synopsis
- Real-world data (RWD) are crucial for enhancing clinical trial (CT) findings, but challenges like data quality persist; the REALYSA study, launched in 2018, focuses on newly diagnosed lymphoma patients in France.
- A proof-of-concept analysis of 645 patients with diffuse large B-cell lymphoma (DLBCL) found high data completeness (<4% missing) and revealed good survival rates, with a median follow-up of 9.9 months showing 1-year event-free survival of 77.9% and overall survival of 90.0%.
- The study also assessed how well REALYSA's patient outcomes matched those from recent phase 3 trials (POLARIX and SENIOR), demonstrating
Article Synopsis
- The French hospital system is facing a crisis due to staff shortages, prompting department heads to seek collaborative solutions for maintaining patient care.
- A two-day seminar was held for fourteen hematology department heads, focusing on sharing experiences and fostering a community aimed at improving their hospitals.
- The participants expressed interest in expanding collaboration through regular seminars for department heads across various specialties, aligning with public service strategies to strengthen hospital departments and inspire broader change in the health system.
Purpose Of Review: The aim of this review is to provide an update on current first-line treatments as well as on-going studies in immunocompetent patients with primary central nervous system lymphomas.
Recent Findings: High-dose methotrexate (HD-MTX)-based polychemotherapy is widely used in induction treatment (IT). Among HD-MTX-based regimens, the best association is not yet defined.
Article Synopsis
- A study on elderly patients with primary central nervous system lymphoma (PCNSL) showed that using special PET and MRI scans can help improve their treatment management.
- Researchers looked at 54 patients and found that many had aggressive tumors, but 69% responded well to chemotherapy.
- The study also found that certain scan results could predict survival rates, with some sizes of the tumors indicating a higher risk of early death.
Whole brain radiotherapy (WBRT) has long been a key treatment of newly diagnosed primary central nervous system lymphoma (PCNSL). In the 1990s, the addition of high dose Methotrexate-based induction chemotherapy (HD MTX-based CT) has enabled a drastic improvement in PCNSL patients outcome. However, combined treatment has led to radiation-induced delayed neurotoxicity, especially in older patients.
View Article and Find Full Text PDFIn this review focused on lymphoma and the central nervous system (CNS), we summarize recent developments in the management of primary (PCNSL) and secondary CNS lymphoma (SCNSL), treatment of CNS lymphoma in the older population, the neuroradiological assessment of CNS lymphoma and finally highlight the ongoing debate on optimal CNS prophylaxis. The section on PCNSL focuses on the different approaches available for frontline treatment in Europe and the United States and discusses consolidation strategies. We then highlight available strategies to treat PCNSL in the elderly population, an area of unmet need.
View Article and Find Full Text PDFArticle Synopsis
- The study looked at how doctors treat a type of brain cancer called primary central nervous system lymphoma (PCNSL) using radiation therapy.
- Researchers checked the records of 79 patients who had this treatment between 2011 and 2018, and found that many doctors didn’t follow the recommended radiation doses and areas that should be treated.
- The study suggests that doctors should better follow guidelines for radiation to help patients survive longer and avoid cancer coming back, and they recommend updating these guidelines.